Clinical trials: Alopecia Areata
Frontal Fibrosing Alopecia
Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia
The purpose of this study is to determine the efficacy of treatment with intralesional injection of corticosteroids on the treatment of Frontal Fibrosing Alopecia (compared with placebo), between three months, six months and…
- Trial name
- FFA (NCT02467101)
- Testing
- Corticosteroid/Saline
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Rubina Alves
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA2 (NCT04797650)
- Testing
- CTP-543
- Where
- 63 sites in United States, Canada and 5 more
- Volunteers
- 517 people
- Sponsor
- Concert Pharmaceuticals
Lichen Planopilaris of Scalp, Lichen Plano-Pilaris
Design and Validation of a New Assessment Tool for Lichen Planopilaris
The study's Primary Objective is to design and validate a grading system for objective and accurate assessment of lichen planopilaris.
- Conditions
- Lichen Planopilaris of Scalp, Lichen Plano-Pilaris, Lichen Planopilaris, Frontal Fibrosing Alopecia
- Trial name
- NCT03082560
- Testing
- Boston Grade of Activity in Lichen Planopilaris
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Chemotherapy Adjuvant, Breast Cancer
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
The efficacy and safety of the Dignicap System to prevent chemotherapy induced alopecia will be evaluated in women with early breast cancer undergoing adjuvant or neoadjuvant chemotherapy regimens.
- Trial name
- NCT01831024
- Testing
- Dignicap System
- Where
- 4 sites in United States
- Volunteers
- 110 people
- Sponsor
- Target Health Inc.
Alopecia Areata
Combined Microneedling and Topical Pentoxifylline Vesrus Intalesional Pentoxifylline in Treatment of Alopecia Areata: Intra-indiviual Comparative Study
Alopecia areata (AA) is a common autoimmune disease that targets hair follicles with a prevalence of approximately 0.1% and a lifetime incidence of approximately 1.7%. AA is the third most prevalent nonscarring hair loss disease.
- Trial name
- NCT05502952
- Testing
- Pentoxifylline
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Atopic Dermatitis, Dermatology
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions
The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting.
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata
- Trial name
- ClinPRO-DERM (NCT05084417)
- Testing
- N/A This is an observational study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- OM1, Inc.
Alopecia Areata
A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
The purpose of this study is to determine if receiving sub-cutaneous injections of a medication called abatacept causes regrowth of hair in people with alopecia areata.
- Trial name
- NCT01917058
- Testing
- Abatacept
- Where
- United States
- Sponsor
- Columbia University
Alopecia Areata, Alopecia Totalis
Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata
This study is a randomized, double-blind, placebo-controlled, multi-center, dose-ranging study to characterize the efficacy and safety of BNZ-1 administered by slow IV push weekly for 3 months to adults diagnosed with moderate to…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT03532958
- Testing
- BNZ-1, Normal saline
- Sponsor
- Equillium
Androgenetic Alopecia (AGA), Telogen Effluvium
Therapeutic Potential of Topical Latanoprost Acid in Hair Loss - Pilot, Proof-of-concept Study
This pilot study evaluates the efficacy, safety, and tolerability of topical latanoprost acid in adult women with female pattern hair loss, with a minority of participants diagnosed with chronic telogen effluvium.
- Conditions
- Androgenetic Alopecia (AGA), Telogen Effluvium, Female Pattern Hair Loss, Androgenic Alopecia
- Trial name
- NCT07412587
- Testing
- Latanoprost acid-containing cosmetic topical solution
- Volunteers
- 29 people
- Sponsor
- Medical University of Warsaw
Severe Alopecia Areata
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
The purpose of this study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the possible treatment of severe alopecia areata. Alopecia areata is a condition that causes hair loss.
- Trial name
- B7981027 (NCT07029711)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 83 sites in United States, China and 7 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Alopecia Areata
A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.
- Trial name
- BRAVE-AA1 (NCT03570749)
- Testing
- Baricitinib
- Where
- 75 sites in United States, Japan and 3 more
- Volunteers
- 784 people
- Sponsor
- Eli Lilly and Company
Hair Health, Hair Loss
A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health
This clinical trial aims to investigate the effectiveness of two Vitamins Revive hair supplements in promoting hair growth, reducing hair loss, and improving overall hair health.
- Trial name
- NCT06120933
- Testing
- Hair Nutra Growth Supplement & Hair Nutra Boost Supplement, Hair Nutra Growth
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BrandiZone
Alopecia Areata
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata
The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
- Trial name
- BRAVE-AA2 (NCT03899259)
- Testing
- Baricitinib
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Alopecia Areata
A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
This first in human phase 1 study to Study will evaluate safety, tolerability, and pharmacokinetics of Single Ascending dose (SAD), Food effect (FE) and Multiple ascending dose (MAD) of OR-101 Administered Orally in healthy…
- Trial name
- NCT06045624
- Testing
- OR-101 (Single ascending dose), OR-101 (Food effect), OR-101 (Multiple ascending dose)
- Where
- Australia
- Volunteers
- healthy volunteers welcome
- Sponsor
- Ornovi, Inc.
Androgenetic Alopecia
Treatment of Androgenetic Alopecia in Males and Females
The purpose of this study is to evaluate the efficacy of Low Level Laser and Light Therapy system configured in a novel product called the TopHat 655 system, for promoting hair growth in males and females diagnosed with…
- Trial name
- LLLT (NCT01437163)
- Testing
- TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
- Where
- 4 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Apira Science, Inc.
Central Centrifugal Cicatricial Alopecia
Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)
This is a single-center, open-label clinical study to study the efficacy of apremilast in the treatment of mild to moderate central centrifugal cicatricial alopecia.
- Trial name
- NCT03521687
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Frontal Fibrosing Alopecia, Cicatricial Alopecia
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often used to treat FFA, but it is not…
- Trial name
- NCT07190534
- Testing
- Hydroxychloroquine (HCQ), Methotrexate (MTX)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Androgenetic Alopecia, AGA
Efficacy and Safety of VDPHL01 in Males With AGA
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to…
- Conditions
- Androgenetic Alopecia, AGA, Male Pattern Baldness
- Trial name
- NCT06724614
- Testing
- VDPHL01
- Where
- 44 sites in United States
- Volunteers
- 480 people
- Sponsor
- Veradermics, Inc.
Alopecia, Androgenetic, Healthy
Assessment of Biological and Biometrological Parameters in Adult Subjects with Androgenetic Alopecia
Androgenetic alopecia is a chronic pathology affecting approximately 50% of men at 50 years old and is characterized by a progressive miniaturization of the hair follicle leading to a localized baldness.
- Trial name
- NCT06854432
- Testing
- Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique